Editorial
Published in the journal:
Vnitř Lék 2022; 68(2): 79
Category:
Editorial
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2022 Číslo 2
Najčítanejšie v tomto čísle
- Oral semaglutide – Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
- The position of SGLT2 inhibitors in current medical practice – update 2022
- Prediabetes
- Anticoagulation in cancer patients; new recommendations based on randomized clinical trials